Satellos Bioscience Inc.
MSCL.V
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.95M
Close$
Share Statistics
| Market cap | $10.95 Million |
|---|---|
| Enterprise Value | $3.57 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -57.12% |
|---|---|
| Return on Assets | -52.03% |
| Return on Invested Capital | -59.12% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Satellos Bioscience Inc. Common Stock
14 employees
CEO: Francis Gleeson Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based reg...